Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

PURPOSE: To evaluate a new class of blood-based biomarkers, anti-frameshift peptide antibodies, for predicting both tumor responses and adverse immune events to immune checkpoint inhibitor (ICI) therapies in advanced lung cancer patients. EXPERIMENTAL DESIGN: Serum samples were obtained from 74 lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Luhui, Brown, Justin R., Johnston, Stephen Albert, Altan, Mehmet, Sykes, Kathryn F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201711/
https://www.ncbi.nlm.nih.gov/pubmed/37217961
http://dx.doi.org/10.1186/s12967-023-04172-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201711/
https://www.ncbi.nlm.nih.gov/pubmed/37217961
http://dx.doi.org/10.1186/s12967-023-04172-w

Ejemplares similares